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Abstract
Background
Few studies have evaluated the association between preexisting vitamin D deficiency and
incident tuberculosis (TB). We assessed the impact of baseline vitamins D levels on TB dis-
ease risk.
Methods and findings
We assessed the association between baseline vitamin D and incident TB in a prospective
cohort of 6,751 HIV-negative household contacts of TB patients enrolled between Septem-
ber 1, 2009, and August 29, 2012, in Lima, Peru. We screened for TB disease at 2, 6, and
12 months after enrollment. We defined cases as household contacts who developed TB
disease at least 15 days after enrollment of the index patient. For each case, we randomly
selected four controls from among contacts who did not develop TB disease, matching on
gender and year of age. We also conducted a one-stage individual-participant data (IPD)
meta-analysis searching PubMed and Embase to identify prospective studies of vitamin D
and TB disease until June 8, 2019. We included studies that assessed vitamin D before TB
diagnosis. In the primary analysis, we defined vitamin D deficiency as 25–(OH)D < 50 nmol/
L, insufficiency as 50–75 nmol/L, and sufficiency as >75nmol/L. We estimated the associa-
tion between baseline vitamin D status and incident TB using conditional logistic regression
in the Lima cohort and generalized linear mixed models in the meta-analysis. We further
defined severe vitamin D deficiency as 25–(OH)D < 25 nmol/L and performed stratified anal-
yses by HIV status in the IPD meta-analysis. In the Lima cohort, we analyzed 180 cases and
709 matched controls. The adjusted odds ratio (aOR) for TB risk among participants with
baseline vitamin D deficiency compared to sufficient vitamin D was 1.63 (95% CI 0.75–3.52;
p = 0.22). We included seven published studies in the meta-analysis and analyzed 3,544
participants. In the pooled analysis, the aOR was 1.48 (95% CI 1.04–2.10; p = 0.03). The
aOR for severe vitamin D deficiency was 2.05 (95% CI 0.87–4.87; p trend for decreasing
25–(OH)D levels from sufficient vitamin D to severe deficiency = 0.02). Among 1,576 HIV-
positive patients, vitamin D deficiency conferred a 2-fold (aOR 2.18, 95% CI 1.22–3.90; p =
0.01) increased risk of TB, and the aOR for severe vitamin D deficiency compared to suffi-
cient vitamin D was 4.28 (95% CI 0.85–21.45; p = 0.08). Our Lima cohort study is limited by
the short duration of follow-up, and the IPD meta-analysis is limited by the number of possi-
ble confounding covariates available across all studies.
Conclusion
Our findings suggest vitamin D predicts TB disease risk in a dose-dependent manner and
that the risk of TB disease is highest among HIV-positive individuals with severe vitamin D
deficiency. Randomized control trials are needed to evaluate the possible role of vitamin D
supplementation on reducing TB disease risk.
Vitamin D and incident TB
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Author summary
Why was this study done?
• Although multiple lines of evidence suggest that vitamin D may play a role in host sus-
ceptibility to tuberculosis (TB) disease, the impact of low vitamin D on the risk of devel-
oping TB disease has not yet been firmly established.
What did the researchers do and find?
• We conducted a study in Lima, Peru, in which we measured serum 25–(OH)D levels in
individuals at high risk for TB disease and followed them for development of TB over 1
year.
• We pooled individual-level data from seven previously published prospective studies
conducted worldwide and from our Lima cohort.
• We found that individuals with low levels of vitamin D were at higher risk of future pro-
gression to TB disease.
What do these findings mean?
• These findings suggest that vitamin D deficiency is a risk factor for developing TB
disease.
• Randomized control trials are needed to determine whether vitamin D supplementation
reduces risk of TB disease.
Introduction
The global burden of tuberculosis (TB) remains high, with approximately one-fourth to one-
third of the world’s population infected with Mycobacterium tuberculosis (MTB), and the
World Health Organization (WHO) estimates 10 million people developed TB disease in 2017
[1]. Concurrently, vitamin D deficiency (VDD) is a widespread problem globally, with a high
degree of geographic variability; reported adult prevalence of VDD ranges from 10% in North
America to>80% in parts of Asia [2,3]. Vitamin D is an important regulator of the immune
system [4], and in vitro studies have elucidated multiple mechanisms by which vitamin D
influences the pathogenesis of TB infection or disease [5–8]. At the level of the macrophage,
vitamin D is involved in cathelicidin- and interferon gamma (IFN-γ)-mediated activity against
mycobacteria, [5,6], induction of oxidative species [7], and the promotion of phagolysosome
fusion, which leads to degradation of mycobacteria [8]. Discoveries about the various ways
vitamin D modulates specific host immune responses to TB infection have focused attention
on the possibility that low vitamin D levels may contribute to TB disease progression.
Numerous observational studies have also documented lower serum vitamin D levels
among TB patients compared to healthy controls, and prior meta-analyses investigating the
association between vitamin D and TB have concluded that low vitamin D increases TB dis-
ease risk [9–12]. However, most studies were cross-sectional studies and assessed vitamin D
Vitamin D and incident TB
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status after the diagnosis of active TB disease, rather than the impact of preexisting vitamin D
levels on the risk of progression to TB disease. Given TB disease can induce profound meta-
bolic abnormalities, it is unclear whether VDD increases TB disease risk or whether underlying
TB infection or disease leads to decreased serum 25–(OH)D levels. Furthermore, prior studies
evaluating the association between vitamin D and TB disease have used different cutoffs to cat-
egorize vitamin D levels or define VDD [9–12]. Hence, it is challenging to determine whether
there is a vitamin D threshold below which individuals are at the greatest risk of TB disease.
Here, we address the association of vitamin D status on the risk of TB progression in two
ways. We first report results of a case-control analysis nested in a prospective cohort study of
household contacts (HHCs) of TB patients that we conducted in Lima, Peru. We next pool
these data with those from other published prospective studies of vitamin D status and TB risk
to conduct an individual-participant data (IPD) meta-analysis synthesizing available evidence
on the association between vitamin D status and incident TB disease.
Methods
Lima cohort study
Ethics statement. The Lima cohort study was approved by the Institutional Review Board
of Harvard School of Public Health and the Research Ethics Committee of the National Insti-
tute of Health of Peru. All study participants or guardians provided written informed consent.
Study setting and population. We enrolled a prospective longitudinal cohort of HHCs of
index TB patients in Lima, Peru, between September 1, 2009, and August 29, 2012, for a parent
study that was designed to identify various host risk factors for TB infection and disease after
exposure. We performed secondary analyses nested in this longitudinal cohort evaluating nutri-
tional determinants of TB disease; we did not follow a prespecified protocol for these secondary
analyses of nutritional risk factors. We provide a STROBE checklist of items specific to case-
control analyses (S1 Text). Details of the nested study design and methods are described else-
where [13,14]. At the time of diagnosis of an index patient, HHCs were assessed for symptoms
of TB (fever, night sweats, weight loss, cough, malaise) and underwent a brief physical exam
(lung auscultation, assessment for lymphadenopathy and signs of recent weight loss) conducted
by a clinician to rule out TB disease. We referred those with any signs or symptoms of TB for
diagnostic evaluation with chest radiograph as well as sputum smear microscopy and mycobac-
terial culture according to Peru’s national guidelines [15]. Among HHCs without a prior history
of TB infection or disease, we assessed baseline TB infection status with the tuberculin skin test
(TST). We used a structured questionnaire to obtain clinical, sociodemographic, and environ-
mental information from HHCs. We offered all HHCs HIV testing. We also invited HHCs to
provide a baseline blood sample; 60% of HHCs aged 10 years and older complied. According to
national guidelines [15], local healthcare staff offered isoniazid preventive therapy (IPT) to all
children under 5 years of age, to TST-positive children between ages 5 and 19 years, and to
adults with specified comorbidities (HIV, malignancies, immune deficiencies).
We visited households and reevaluated all HHCs for pulmonary and extrapulmonary TB
disease at 2, 6, and 12 months after enrollment. We classified HHCs as having incident second-
ary TB disease if they were diagnosed at least 15 days after index case enrollment and co-preva-
lent TB disease if they were diagnosed earlier.
At the completion of follow-up, we identified “cases” from among the HHC cohort; these
were HIV-negative HHCs with blood samples who developed incident secondary TB disease
within 1 year of follow-up. For each case, we randomly selected four controls from among
HHCs who were not diagnosed with TB disease during the study period, matching on gender
and age by year.
Vitamin D and incident TB
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Laboratory methods. We stored all blood samples at −80˚C from enrollment until end of
follow-up. All samples were handled identically, and laboratory personnel were not aware of
the case or control status of specimens. Levels of total 25–(OH)D were measured with a com-
mercial competitive enzyme immunoassay kit (Immunodiagnostic Systems, Fountain Hills,
AZ, United States), which is sensitive to 5.0 nmol/L. The interassay coefficient of variation for
25–(OH)D ranged from 4.6% to 8.7%. We also measured retinol levels using the high-perfor-
mance liquid chromatography (HPLC) method described by El-Sohemy and colleagues [16].
Since testing of all blood samples occurred after the end of study follow-up, participants were
not diagnosed with VDD during study period and were not offered supplementation.
Statistical analysis. We defined VDD as serum 25–(OH)D < 50 nmol/L, vitamin D insuf-
ficiency (VDI) as 50–75 nmol/L, and sufficiency as>75 nmol/L [17]. We defined vitamin A
deficiency (VAD) as serum retinol< 200 μg/L [18]. We classified adults� 20 years old as
underweight (body mass index [BMI] < 18.5 kg/m2), normal weight (BMI 18.5–<25 kg/m2),
and overweight (BMI� 25 kg/m2). For children and adolescent HHCs < 20 years, we used
WHO age- and gender-specific BMI z-scores tables to classify those with BMI z-score < −2 as
underweight and those with z-score> 2 as overweight [19]. We conducted a principal compo-
nents analysis that included housing type, number of rooms, water supply, sanitation facilities,
lighting, composition of exterior walls and floor, and roof materials weighted by household
size to compute a socioeconomic status (SES) score, which was then categorized into tertiles
[20]. We classified HHCs as ever TB infected at baseline if they reported history of TB disease
or positive TST or had a TST result� 10 mm at enrollment.
In Lima, Peru, the monthly average temperature ranges between 24 and 26˚C from January
to April and starts to decrease in May, reaching an annual low temperature (18˚C) in August;
and temperatures begin to rise again in October [21]. Based on this yearly pattern, we classified
a year into three seasons: winter (June through September), spring (October through Decem-
ber), and summer (January through May).
We used univariate and multivariate conditional logistic regression models (adjusting
for matching factors) to evaluate the association between baseline vitamin D status and risk
of TB disease [22]. Multivariate models included baseline covariates identified a priori as
potential confounders. We used complete case analysis in the regression models. Because we
had previously observed that VAD increases risk of TB disease in this cohort [13], we also
adjusted for retinol levels and evaluated the interaction between VAD and VDD on incident
TB risk.
In sensitivity analyses, we repeated our regressions, restricting the analysis to people who
developed incident TB that was diagnosed at least 60 days after enrollment of index patient
and their matched controls. We also performed a sensitivity analysis in which we included
only patients with microbiologically confirmed TB and their matched controls.
Based on peer review feedback, we further examined the association between VDD and risk
of incident TB diagnosed less than 60 days after index case enrollment.
Data were analyzed using SAS v9.4 (SAS Institute, Cary, NC, USA, 2013)
Systematic review and IPD meta-analysis
Upon completing our nested case-control study analysis, we conducted a systematic review of
prior prospective studies investigating the association between vitamin D status and incident
TB disease. After identifying fewer than 10 studies, most of which were conducted in small
cohorts and used different thresholds for categorizing vitamin D, we undertook an IPD meta-
analysis to harmonize the definition of VDD and increase the power to detect differences in
risk of TB by vitamin D status.
Vitamin D and incident TB
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Search strategy and data sources. We conducted the systematic review and meta-analysis
according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRIMSA) guidelines (S2 Text, S3 Text) [23,24]. All studies included in the IPD meta-analysis
received relevant institutional or country-specific ethics approval, and participants provided
written or oral informed consent.
We initially searched the PubMed database via the NCBI Entrez system (https://www.ncbi.
nlm.nih.gov/pubmed) and Embase (https://www.embase.com) for all available studies up to
December 31, 2017, on the association between vitamin D and incident TB disease. Box 1 pro-
vides details of our search strategy.
We updated the search during peer review process to identify additional eligible studies
published between January 1, 2018, and June 8, 2019.
Study eligibility and inclusion criteria. We placed no restrictions on language. We
included all prospective longitudinal studies of human participants at risk for TB if the study
measured vitamin D levels in baseline blood samples obtained prior to a diagnosis of TB dis-
ease. Studies were included if they confirmed TB diagnosis by microbiological criteria or speci-
fied their clinical criteria for ascertaining TB disease and if they collected data on age and
gender. We considered any clinical criteria for TB disease based on physician assessment,
imaging studies, or national guidelines. We did not place restrictions on laboratory method
used to assess vitamin D levels and did not require studies to control for possible confounders.
Box 1. Search strategy for studies on the association between vitamin D
and incident TB disease
PubMed
Mesh Terms:
1. “Vitamin D” OR “Vitamin D deficiency” AND
2. Tuberculosis
OR
Text Terms:
3. “Vitamin D” OR “Vitamin D deficiency” OR “hypovitaminosis D” OR “25-hydro-
xyvitamin D” OR “1,25-dihydroxyvitamin D” OR “Vitamin D2” OR “Vitamin D3”
OR “Ergocalciferol” OR “Cholecalciferol” AND
4. Tuberculosis
Embase
Text Terms:
1. “Vitamin D” OR “Vitamin D deficiency” OR “hypovitaminosis D” OR “25-hydro-
xyvitamin D” OR “1,25-dihydroxyvitamin D” OR “Vitamin D2” OR “Vitamin D3”
OR “Ergocalciferol” OR “Cholecalciferol” AND
2. Tuberculosis
Vitamin D and incident TB
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We also considered reports from conference abstracts. We excluded the following: case
reports, animal or in vitro studies, case-control or cross-sectional studies that measured vita-
min D levels among individuals already diagnosed with TB disease, studies that did not report
vitamin D levels, studies of other diseases or non-TB-related outcomes, studies of vitamin D
and TB treatment outcomes or TB infection or TB immune reconstitution inflammatory syn-
drome (IRIS), reviews, meta-analyses, letters, editorials, and protocols.
Data collection and data items. For each eligible study, two reviewers (OA and SC)
independently performed full text reviews and extracted the following information: first
author’s last name, year of publication, study design and study aim, country of study, calen-
dar years of study, length of follow-up, number of incident TB cases, total number of subjects
analyzed, criteria for diagnosing TB disease, laboratory method of vitamin D assay, method
of categorizing vitamin D, assessment of HIV status, and covariates in multivariate analyses.
Discrepancies were resolved by consensus.
We contacted all authors of the eligible studies identified from the systematic review and
requested IPD. Lead investigators from all the studies agreed to provide data for analysis. Data
were de-identified prior to transfer via email. We requested all available data on possible con-
founders of the association between vitamin D and TB disease, including age, gender, HIV sta-
tus, weight, height, BMI, IPT, baseline TST result, TB disease history, and comorbid diseases.
We also requested baseline vitamin D levels, incident TB disease status during study follow-
up, time from enrollment to TB diagnosis, and index case smear status, if applicable. Data
were reviewed for consistency with published data, and authors were contacted for clarifica-
tions or missing information as needed.
We assessed study quality and risk of bias using the Newcastle-Ottawa Scale (NOS) for
assessing quality of nonrandomized studies in meta-analyses; the NOS evaluates observational
studies on participant selection, comparability of study groups, and ascertainment of exposure
or outcome [25]. Based on the 9-point scoring scale, we classified study quality as good (�7
points), fair (5–6 points), and poor (<5 points).
Statistical analysis. We conducted a one-step IPD meta-analysis combining data from
the eligible studies and from the Peru-based study reported above. We used the unified criteria
described above to categorize BMI and to define VDD as serum 25–(OH)D less than 50 nmol/
L and insufficiency as 50–75 nmol/L. We further defined severe VDD as 25–(OH)D less than
25 nmol/L. To account for geographic variability, we considered datasets from each single-
country study and from each country within a multicountry study as independent data
sources. We used generalized linear mixed univariate and multivariate models to evaluate the
association between baseline vitamin D status and risk of incident TB, including an indicator
for each independent dataset as a random effect to account for within-study correlation. Multi-
variate models were adjusted for age, gender, BMI, and HIV status. Given sparse data on other
variables, we did not adjust for any other potential confounders. We also separately evaluated
the association between severe VDD, compared to sufficient levels, and TB disease risk. To
determine whether the effect of vitamin D on incident TB differed by HIV status, we con-
ducted a stratified analysis. In a sensitivity analysis, we restricted the main analysis to incident
TB cases diagnosed at least 60 days after enrollment. We calculated the Rone-step
2 statistic to
assess heterogeneity [26].
The IPD meta-analysis was conducted using the R package "lme4” [27]. Datasets for the
Lima cohort study and IPD meta-analysis provided as supporting information (S1 Data,
S2 Data).
Vitamin D and incident TB
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Results
Lima cohort study
Among 6,751 HIV-negative HHCs with baseline blood samples, 258 developed TB disease, 66
within 15 days of enrollment and 192 thereafter. Among these 192 secondary TB cases, 152
(79.1%) were microbiologically confirmed, and viable blood samples were available for analysis
for 180 (93.8%) at the end of follow-up (Fig 1). Monthly incident of TB cases is shown in S1
Fig. Among the 180 TB cases analyzed, 147 (81.7%%) were microbiologically confirmed.
Table 1 lists baseline characteristics of the incident cases and their matched controls. The
median levels of 25–(OH)D at baseline were similar among cases (53.9 nmol/L; interquartile
range [IQR] 42.7–64.0 nmol/L) and controls (54.7 nmol/L; IQR 44.5–67.1 nmol/L; p = 0.32)
(Table 2). Median serum 25–(OH)D levels during spring/summer (57.2 nmol/L; IQR 46.1–
69.0 nmol/L) were higher than during winter (49.6 nmol/L; IQR 40.5–59.9 nmol/L; p< 0.001)
(S2 Fig).
Fig 1. Flow diagram for selection of cases and controls in Lima cohort. HHC, household contact; TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1002907.g001
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Table 1. Baseline characteristics of participants in Lima cohort study.
Characteristic Cases, n (%) Na (Cases) Controls,
n (%)
Na (Controls) Nonmatched Household Contacts, n (%) Na (Household Contacts)
Age categories in years 180 709 5,796
0–14 15 (8.3) 60 (8.5) 600 (10.4)
15–24 74 (41.1) 298
(42.0)
1,380 (23.8)
�25 91 (50.6) 351
(49.5)
3,816 (65.8)
Male 94 (52.2) 366
(51.6)
2,413 (41.6)
BMI categoriesb 179 706 5,745
Underweight 8 (4.5) 6 (0.9) 64 (1.1)
Overweight 45 (25.1) 299
(42.4)
2,881 (50.2)
Normal 126 (70.4) 401
(56.8)
2,800 (48.7)
SESc 171 698 5,607
Lowest tertile 77 (45.0) 228
(32.7)
1,847 (32.9)
Middle tertile 66 (38.6) 326
(46.7)
2,565 (45.8)
Highest tertile 28 (16.4) 144
(20.6)
1,195 (21.3)
Heavy alcohol used 14 (8.1) 174 64 (9.3) 692 444 (7.9) 5,632
Current smoking 13 (7.4) 176 78 (11.2) 699 488 (8.5) 5,711
Self-reported diabetes 6 (3.4) 179 11 (1.6) 701 135 (2.4) 5,739
Comorbid diseasee 37 (20.6) 180 175
(24.7)
709 1,380 (23.8) 5,795
Isoniazid preventive therapy 7 (3.9) 180 108
(15.2)
709 713 (12.3) 5,790
BCG scar 159 (88.3) 180 628
(88.6)
709 5,133 (88.6) 5,795
History of TB 34 (18.9) 55 (7.8) 708 545 (9.4) 5,782
Baseline TST positive (�10 mm) 85 (71.4) 119 255
(39.4)
647 2,498 (46.6) 5,362
Ever TB infected at baseline 145 (82.4) 176 281
(41.1)
683 2,768 (49.0) 5,649
Mean days to TB diagnosis (± SD) 118.5 (±114.5) 180 NA
NA
Median days to TB diagnosis
(IQR)
66.0 (20.5–
198.0)
180 NA NA
Season of blood sample collection 180 709
5,796
Spring/summer 136 (75.6) 483
(68.1)
3,821 (65.9)
Winter 44 (24.4) 226
(31.9)
1975 (34.1)
Index Patient Characteristics
Smear positive 156 (86.7) 180 486
(68.7)
707 4,150 (71.6) 5,793
(Continued)
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In the univariate analysis, the differences in the risk of incident TB disease among HHCs
with baseline VDD and baseline VDI compared to those with sufficient levels were not statisti-
cally significant (odds ratio [OR] VDD 1.54; 95% CI 0.88–2.71; p = 0.13 and OR VDI 1.23;
95% CI 0.72–2.08; p = 0.45) (Table 3). After we adjusted for BMI categories, SES, heavy alcohol
consumption, tobacco use, IPT, TB infection status, comorbid disease, self-reported DM,
index patient smear status, and season of sample collection, compared to those with sufficient
vitamin D levels, the ORs for HHCs with baseline VDD and VDI were 1.63 (95% CI 0.75–3.52;
p = 0.22) and 1.12 (95% CI 0.57–2.23; p = 0.75), respectively (Table 3). When we further
adjusted for VAD, the ORs for HHCs with VDD and VDI were 1.59 (95% CI 0.71–3.55;
p = 0.26) and 1.12 (95% CI 0.55–2.27; p = 0.75), respectively. A test for interaction between
VAD and VDD was not statistically significant (p for interaction = 0.07) (S1 Table).
Our conclusions did not differ from results of the main analysis when we restricted our
analyses to cases (and matched controls) diagnosed at least 60 days after index patient enroll-
ment or to microbiologically confirmed TB cases (Table 4). We did not find a statistically sig-
nificant association between VDD and risk of TB diagnosed less than 60 days after index case
enrollment (OR 0.98; 95% CI 0.20–4.72; p = 0.98).
Systematic review and IPD meta-analysis
We identified 2,689 citations from the initial PubMed and Embase searches through December
31, 2017. After screening titles and abstracts, we excluded 2,678 articles because they were
Table 1. (Continued)
Characteristic Cases, n (%) Na (Cases) Controls,
n (%)
Na (Controls) Nonmatched Household Contacts, n (%) Na (Household Contacts)
Cavitary disease 54 (30.2) 179 175
(25.1)
697 1,424 (24.9) 5,722
a Total number of subjects with data for corresponding variable.
b We classified adults� 20 years old as underweight (BMI < 18.5 kg/m2), normal weight (BMI 18.5–<25 kg/m2), and overweight (BMI � 25 kg/m2). For children and
adolescents < 20 years old, we used WHO age- and gender-specific BMI z-scores tables to classify those with BMI z-score < –2 as underweight and those with z-
score > 2 as overweight.
c We conducted a principal components analysis that included housing type, number of rooms, water supply, sanitation facilities, lighting, composition of exterior walls
and floor, and roof materials weighted by household size to compute an SES score, which was then categorized into tertiles [20].
d Self-reported consumption of�40 g or�3 alcoholic drinks daily.
e Heart disease, high blood pressure, asthma, kidney disease, use of steroids or chemotherapy or immunosuppressant, any other self-reported chronic illness.
Abbreviations: BCG, Bacillus Calmette–Gue´rin; BMI, body mass index; IQR, interquartile range; SES, socioeconomic status; TB, tuberculosis; TST, tuberculin skin test;
WHO, World Health Organization
https://doi.org/10.1371/journal.pmed.1002907.t001
Table 2. Baseline levels of vitamin D among cases and controls in Lima cohort study.
Vitamin D levels Cases (N = 180)
Median (IQR) or n (%)
Control (N = 709)
Median (IQR) or n (%)
p-Valuea
25–OH Vitamin D (nmol/L) 53.9 (42.7–64.0) 54.7 (44.5–67.1) 0.32
Vitamin D deficient (<50 nmol/L) 76 (42.2) 259 (36.5) 0.13
Vitamin D insufficient (50–75 nmol/L) 84 (46.7) 348 (49.1) 0.45
Vitamin D sufficient (>75 nmol/L) 20 (11.1) 102 (14.4) 1.00
a Univariate p values adjusted for matching factors (age and sex).
Abbreviation: IQR, interquartile range
https://doi.org/10.1371/journal.pmed.1002907.t002
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reviews, meta-analyses, letters, editorials or protocols (n = 1,212), case reports (n = 515), stud-
ies of other diseases or other outcomes (n = 331), animal or in vitro studies (n = 247), case-
control or cross-sectional studies that assessed vitamin D status after TB disease diagnosis (n =
159), studies that did not measure vitamin D (n = 144), studies of TB treatment outcomes (n =
63), and studies of TB infection (n = 7) (Fig 2). We reviewed full texts of the remaining 11 arti-
cles [28–38] and further excluded three studies that assessed outcomes of TB-IRIS [35–37] and
one study of TB infection with seasonality of TB [38]. Table 5 provides information about the
seven eligible published studies [28–34] identified from the systematic review through Decem-
ber 31, 2017. All seven studies included in the IPD meta-analysis attained at least seven points
on the NOS scale and were categorized as “good quality” studies (S2 Table).
In the updated search during peer review, we identified one additional eligible study pub-
lished between January 1, 2018, and June 8, 2019, that had not been included in the IPD meta-
analysis [39]. Details are provided as supporting information (S3 Fig, S3 Table).
We obtained IPD from all eligible seven studies published through December 31, 2017.
One study provided patient data from a multisite evaluation conducted in nine countries [34].
Six of the seven studies were prospective cohort or case-cohort studies [28, 29, 31–34], whereas
one study was a nested case-control study [30]. The final combined dataset with our Lima
cohort study included 3,544 participants from 13 countries: Brazil, The Gambia, Haiti, India,
Malawi, Pakistan, Peru, South Africa, Spain, Tanzania, Thailand, US, and Zimbabwe. We
Table 3. Association between vitamin D status and risk of TB disease among household contacts of TB patients in Lima cohort study.
Vitamin D status Cases/Controls Univariate OR (95% CI) N = 889 p-Value Multivariate ORa (95% CI) N = 822 p-Value
Vitamin D deficient (<50 nmol/L) 76/259 1.54 (0.88–2.71) 0.13 1.63 (0.75–3.52) 0.22
Vitamin D insufficient (50–75 nmol/L) 84/348 1.23 (0.72–2.08) 0.45 1.12 (0.57–2.23) 0.74
Vitamin D sufficient (>75 nmol/L) 20/102 1.00 1.00
a Adjusted for matching factors (age and sex), BMI categories, socioeconomic status, heavy alcohol consumption, tobacco use, isoniazid preventive therapy, ever TB
infected, comorbid disease, self-reported DM, index patient smear status, and season of sample collection.
Abbreviations: BMI, body mass index; DM, type 2 diabetes mellitus; OR, odds ratio; TB, tuberculosis
https://doi.org/10.1371/journal.pmed.1002907.t003
Table 4. Vitamin D status and risk of TB disease stratified by date of TB diagnosis and microbiologically confirmed TB in Lima cohort study.
Timing of TB diagnosis or TB type Cases/Controls Multivariate ORa (95% CI) p-Value
TB diagnosed < 60 days
Vitamin D deficient (<50 nmol/L) 50/172 0.98 (0.20–4.72) 0.98
Vitamin D insufficient (50–75 nmol/L) 34/137 1.12 (0.28–4.45) 0.88
Vitamin D sufficient (>75 nmol/L) 5/37 1.00
TB diagnosed� 60 days
Vitamin D deficient (<50 nmol/L) 26/87 1.89 (0.70–5.11) 0.21
Vitamin D insufficient (50–75 nmol/L) 50/211 1.21 (0.52–2.80) 0.65
Vitamin D sufficient (>75 nmol/L) 15/65 1.00
Microbiologically confirmed TB disease
Vitamin D deficient (<50 nmol/L) 60/209 1.91 (0.78–4.70) 0.16
Vitamin D insufficient (50–75 nmol/L) 72/284 1.36 (0.61–3.07) 0.45
Vitamin D sufficient (>75 nmol/L) 15/84 1.00
a Adjusted for matching factors (age and sex), BMI categories, socioeconomic status, heavy alcohol consumption, tobacco use, isoniazid preventive therapy, ever TB
infected, comorbid disease, self-reported DM, index patient smear status, and season of sample collection.
Abbreviations: BMI, body mass index; DM, type 2 diabetes mellitus; OR, odds ratio; TB, tuberculosis
https://doi.org/10.1371/journal.pmed.1002907.t004
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analyzed a total of 456 TB cases. The median time to TB diagnosis from enrollment was 151.0
days (IQR 44.0–342.0 days). Table 6 lists the baseline characteristics of all patients analyzed.
The majority of the participants (86.5%) were over 15 years of age. HIV status was unknown
for 629 (17.7%) patients, whereas 1,711 (48.3%) were HIV positive. One study assessed serum
25–(OH)D levels using HPLC [32], whereas others used immunoassay [28–30,34] and ELISA
Fig 2. Flow diagram for selection of studies for the IPD meta-analysis. IPD, individual-participant data; IRIS, immune reconstitution inflammatory syndrome; TB,
tuberculosis.
https://doi.org/10.1371/journal.pmed.1002907.g002
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Table 6. Baseline demographic and clinical characteristics of participants in the IPD meta-analysis (N = 3,544).
Characteristic n (%) or Median (IQR)
Male 1,520 (42.9)
Age categories in years
0–14 478 (13.5)
15–24 688 (19.4)
�25 2,378 (67.1)
HIV
Positive 1,711 (48.3)
Negative 1,204 (34.0)
Unknown 629 (17.7)
BMI categoriesa
Underweight 433 (12.2)
Overweight 873 (24.6)
Normal 1,858 (52.4)
Unknown 380 (10.7)
Isoniazid preventive therapy
Yes 366 (10.3)
No 2,504 (70.7)
Unknown 674 (19.0)
Baseline tuberculin skin test
Positive (�10 mm) 750 (21.2)
Negative 965 (27.2)
Unknown 1,829 (51.6)
History of TB
Yes 558 (15.7)
No 2,447 (69.1)
Unknown 539 (15.2)
Comorbid diseaseb
Yes 1,224 (34.5)
No 1,181 (33.3)
Unknown 1,139 (32.1)
Index smear status among studies of household contacts of TB casesc
Positive 1,155 (69.6)
Negative 364 (21.9)
Unknown 141 (8.5)
Antiretroviral therapy use among HIV positived
Yes 1,588 (92.8)
No 121 (7.1)
Unknown 2 (0.1)
Baseline CD4 count among HIV positive (cell/μL)e 167 (82–272)
25–OH vitamin D (nmol/L) 65.0 (48.8–83.5)
Vitamin D deficient (<50 nmol/L) 930 (26.2)
Vitamin D insufficient (50–75 nmol/L) 1,357 (38.3)
Vitamin D sufficient (>75 nmol/L) 1,257 (35.5)
a We classified adults� 20 years old as underweight (BMI < 18.5 kg/m2), normal weight (BMI 18.5–<25 kg/m2), and
overweight (BMI � 25 kg/m2). For children and adolescents < 20 years old, we used WHO age- and gender-specific
BMI z-scores tables to classify those with BMI z-score < −2 as underweight and those with z-score > 2 as overweight.
b Presence of any other diseases or diagnoses as defined or ascertained in original study.
c N = 1,660.
d N = 1,711.
e N = 1,353.
Abbreviations: BMI, body mass index; IPD, individual-patient data; IQR, interquartile range; TB, tuberculosis;
WHO, World Health Organization
https://doi.org/10.1371/journal.pmed.1002907.t006
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[31,33]. The median baseline level of 25–(OH)D was 65.0 nmol/L (IQR 48.8–83.5 nmol/L).
The prevalence of VDD at baseline was 26.2% and of severe VDD was 4.8%. Most of the partic-
ipants with severe VDD were from studies conducted in Pakistan (35.7%) [33], Spain (25.2%)
[28], and India (17.5%) [30]. Median serum 25–(OH)D levels were higher among HIV-posi-
tive participants (74.3 nmol/L; IQR 58.0–90.0 nmol/L) compared to HIV-negative individuals
(56.5 nmol/L; IQR 44.6–72.5 nmol/L; p< 0.0001). The studies in the IPD meta-analysis did
not collect similar covariates; therefore, we did not compare additional baseline variables by
HIV status.
In the univariate analysis, baseline VDD was associated with a 49% increased risk of pro-
gression to TB disease (OR 1.49; 95% CI 1.07–2.07; p = 0.02), and the OR for VDI compared to
vitamin D sufficiency was 1.26 (95% CI 0.95–1.66; p = 0.11) [Table 7]. Both VDD and VDI
remained associated with an increased risk of TB disease after we adjusted for age, gender,
BMI, and HIV status (adjusted OR [aOR] for VDD: 1.48; 95% CI 1.04–2.10; p = 0.03; R2 = 0.97
and aOR for VDI: 1.33; 95% CI 1.00–1.78; p = 0.05; R2 = 0.98).
When we stratified by HIV status, HIV-positive individuals with VDD were twice as likely
to develop TB disease compared to those with normal levels (aOR 2.18; 95% CI 1.22–3.90;
p = 0.01; R2 = 0.97), whereas the aOR for TB disease among HIV-negative participants with
VDD was 1.20 (95% CI 0.74–1.93; p = 0.46; R2 = 0.99) (Table 8, p for interaction = 0.17).
In the entire IPD cohort, the aOR for incident TB among those with severe VDD was 2.05
(95% CI 0.87–4.87; p trend for stepwise decrease in serum 25–(OH)D levels from sufficient to
severe deficiency = 0.02; R2 = 0.91) (Table 9). Among HIV-positive individuals, the OR for
severe VDD compared to sufficient vitamin D levels was 4.28 (95% CI 0.85–21.45; p = 0.08; R2
= 0.90). In contrast, among HIV-negative individuals, the OR for severe VDD was 1.55 (95%
CI 0.55–4.34; p = 0.41; R2 = 0.97) (Table 9, p for interaction 0.17).
Table 7. Association between selected baseline characteristics and risk of incident TB disease in the IPD meta-
analysis.
Characteristic Univariate ORa (95% CI)
N = 3,544
p-Value Multivariate ORb (95% CI)
N = 2,769
p-Value
BMI categoriesc
Underweight 1.43 (1.02–2.03) 0.04 1.37 (0.95–1.95) 0.09
Overweight 0.41 (0.30–0.55) <0.001 0.40 (0.30–0.56) <0.001
Normal 1.00 1.00
HIV positived 1.44 (0.92–2.25) 0.11 1.22 (0.77–1.95) 0.40
Vitamin D deficient (<50
nmol/L)
1.49 (1.07–2.07) 0.02 1.48 (1.04–2.10) 0.03
Vitamin D insufficient (50–
75 nmol/L)
1.26 (0.95–1.66) 0.11 1.33 (1.00–1.78) 0.05
Vitamin D sufficient (>75
nmol/L)
1.00 1.00
p
trend = 0.02
p
trend = 0.03
a Adjusted for age and gender because of presence of age- and gender-matched case-control study in the combined
dataset.
b Adjusted for age, gender, BMI categories, and HIV status.
c N = 3,164.
d N = 2,915.
Abbreviations: BMI, body mass index; IPD, individual-patient data; OR, odds ratio; TB, tuberculosis
https://doi.org/10.1371/journal.pmed.1002907.t007
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Table 8. Vitamin D deficiency and risk of incident TB disease stratified by HIV status in the IPD meta-analysisa.
HIV Positive HIV Negative
Characteristic N Multivariate ORb
(95% CI)
p-Value N Multivariate ORb
(95% CI)
p-Value
Vitamin D deficient (<50
nmol/L)
146 2.18 (1.22–3.90) 0.01 419 1.20 (0.74–1.93) 0.46
Vitamin D insufficient (50–
75 nmol/L)
623 1.32 (0.90–1.94) 0.16 509 1.18 (0.76–1.84) 0.46
Vitamin D sufficient (>75
nmol/L)
807 1.00 265 1.00
p
trend = 0.01
p
trend = 0.52
BMI categories
Underweight 392 1.02 (0.68–1.54) 0.92 34 3.99 (1.79–8.87) 0.001
Overweight 231 0.41 (0.21–0.78) 0.01 449 0.41 (0.29–0.59) <0.001
Normal 953 1.00 710 1.00
p Test for interaction between HIV status and serum 25–(OH)D levels = 0.17.
a Excluded datasets from Arnedo-Pena and colleagues [28] and Talat and colleagues [33] because of lack of
information on HIV status.
b Adjusted for age, gender, and BMI categories.
Abbreviations: BMI, body mass index; IPD, individual-patient data; OR, odds ratio; TB, tuberculosis
https://doi.org/10.1371/journal.pmed.1002907.t008
Table 9. Severe vitamin D deficiency and risk of incident TB disease stratified by HIV status in the IPD meta-
analysis.
Vitamin D status N Multivariate OR (95% CI) p-Value
All participants (N = 2,769)a
Vitamin D < 25 nmol/L 38 2.05 (0.87–4.87) 0.10
Vitamin D 25–<50 nmol/L 527 1.45 (1.01–2.06) 0.04
Vitamin D insufficient (50–75 nmol/L) 1,132 1.33 (1.00–1.78) 0.05
Vitamin D sufficient (>75 nmol/L) 1,072 Ref
p trend = 0.02
HIV positive (N = 1,576)b
Vitamin D < 25 nmol/L 12 4.28 (0.85–21.45) 0.08
Vitamin D 25–<50 nmol/L 134 2.06 (1.13–3.76) 0.03
Vitamin D insufficient (50–75 nmol/L) 623 1.32 (0.90–1.95) 0.16
Vitamin D sufficient (>75 nmol/L) 807 Ref
p trend = 0.01
HIV negative (N = 1,193)b
Vitamin D < 25 nmol/L 26 1.55 (0.55–4.34) 0.41
Vitamin D 25–<50 nmol/L 393 1.17 (0.73–1.90) 0.51
Vitamin D insufficient (50–75 nmol/L) 509 1.18 (0.76–1.84) 0.46
Vitamin D sufficient (>75 nmol/L) 265 Ref
p trend = 0.46
p Test for interaction between HIV status and serum 25–(OH)D levels = 0.17.
a Model adjusted for age, gender, BMI categories, and HIV status.
b Model adjusted for age, gender, BMI, categories.
Abbreviations: BMI, body mass index; IPD, individual-patient data; OR, odds ratio; TB, tuberculosis
https://doi.org/10.1371/journal.pmed.1002907.t009
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When we separately considered incident cases diagnosed at least 60 days after enrollment,
VDI remained associated with increased risk of TB disease (aOR 1.40; 95% CI 1.02–1.92;
p = 0.04; R2 = 0.97), whereas VDD was no longer associated with incident TB (aOR 1.02; 95%
CI 0.67–1.57; p = 0.92; R2 = 0.95). Only 51.1% of incident TB cases in the IPD meta-analysis
cohort had data on microbiologic confirmation, and we therefore did not conduct a sensitivity
analysis.
In the one publication we identified that appeared after the target dates for the IPD meta-
analysis, Maceda and colleagues [39] reported on a nested case-control study of 72 male pris-
oners in Brazil. Mean 25–(OH)D levels did not differ significantly among cases (92.5 ± 37.0
nmol/L) and controls (93.8 ± 27.5 nmol/L), and there was no association between serum 25–
(OH)D < 75 nmol/L and risk of incident TB disease during 1 year of follow-up (aOR 0.59;
95% CI 0.13–2.62) (S3 Table).
Discussion
Our IPD meta-analysis provides consistent support for a modest dose-dependent effect of vita-
min D on future progression of TB disease across multiple studies conducted in diverse con-
texts. In the IPD, the association of low serum 25–(OH)D levels with increased TB disease risk
was most pronounced among HIV-positive individuals with severe VDD.
Although some previous studies have documented lower vitamin D levels among patients
with active TB compared to healthy controls [9,10,12,40], others have not confirmed the associ-
ation between VDD and increased TB disease risk [11]. Furthermore, even among studies that
found lower vitamin D levels in TB patients compared to healthy controls, the causal direction
of this association is difficult to infer, since TB disease can lead to reduced dietary intake and
micronutrient deficiencies, which resolve with successful treatment [10]. Although a number of
intervention studies have found little evidence of an impact of vitamin D supplementation on
TB treatment outcomes [10,41–46], a recent study demonstrated improved outcomes in a sub-
group of multidrug-resistant patients who received supplementation [47]. In contrast to studies
of micronutrients and TB treatment outcomes [10,41–46], relatively few studies have prospec-
tively investigated the role of preexisting vitamin D status in the development of TB disease.
Our findings in these human studies support the role of vitamin D in TB infection and dis-
ease that has been inferred from more fundamental research that has enumerated multiple
mechanisms by which VDD modulates host immune response to MTB. In macrophages, vita-
min D is implicated in the activation of cathelicidin-mediated killing of ingested mycobacteria
[5,48] induction of IFN-γ-mediated activity in macrophages [6], induction of reactive oxygen
and nitrogen species [7], stimulation of phagolysosome fusion in infected macrophages [8],
and inhibition of matrix metalloproteinases involved in the pathogenesis of cavitary pulmo-
nary TB [49]. Recent evidence has also demonstrated vitamin D is involved in reduced den-
dritic cell–mediated priming of the adaptive immune response [50].
In addition to its impact on immunity, vitamin D status has also been linked to human met-
abolic phenotypes that may be involved in the pathogenesis of TB. In vitro studies have dem-
onstrated various ways by which vitamin D promotes insulin sensitivity [51], and animal
models have shown VDD impairs insulin secretion in pancreatic beta cells [51,52]. Numerous
observational studies have also found an inverse association between vitamin D levels and inci-
dent type 2 diabetes mellitus (DM) [51]. Given DM is a well-described risk factor for TB dis-
ease [53,54], VDD may also contribute to increased TB risk through its role in modifying risk
of diabetes.
Two other lines of evidence point to a possible association between vitamin D and TB.
First, multiple studies have reported an association between specific polymorphisms of vitamin
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D receptor (VDR) and vitamin D binding protein (VDBP) and increased TB risk [10,55–57].
Although it is not clear that the functional effect of these polymorphisms recapitulates the
impact of low vitamin D levels, several studies show that the impact of VDR variants is stron-
ger in the presence of VDD [29,55,58]. Secondly, TB incidence varies with season and peaks in
spring and summer months when vitamin D levels are highest. Some observers have postu-
lated that low levels of sunshine, and hence vitamin D, in winter contribute to an increase in
TB infection followed by a rise in TB disease incidence after a 6-month lag [38,59–61].
We also note previous studies have reported that low vitamin A is a strong predictor of inci-
dent TB disease [34, 62]. Vitamins A and D mediate changes at the cellular level by binding to
nuclear hormone receptors, retinoic acid receptor, and VDR, respectively; and both receptors
bind to retinoid X receptor (RXR) [63]. Some in vitro evidence further suggests vitamins A
and D have synergistic activity in restricting MTB entry and reducing survival within macro-
phages [64]. Although we did not find evidence of a statistically significant interaction between
vitamins A and D deficiencies on risk of TB, our study may not have been powered to detect
this interaction. In a previous analysis of the Lima cohort, we found VAD conferred a 10-fold
increase in TB disease risk [13], and here, we show that adjustment for vitamin A modestly
attenuates the impact of vitamin D. Similarly, Tenforde and colleagues also reported that
adjusting for retinol levels attenuated the effect of vitamin D on TB disease risk [34]. This
raises the possibility that vitamin D levels correlate with other micronutrients implicated in
the pathogenesis of TB, and these micronutrients may be potent mediators of increased TB
risk.
Although we did not detect a statistically significant interaction between vitamin D and
HIV status in the IPD, our findings raise the possibility that the effect of low serum 25–(OH)D
on TB risk may be more pronounced among HIV-positive patients. Studies have shown that
among HIV-infected individuals, VDD is associated with deleterious immune activation [65],
lower CD4 counts [65,66], higher viral loads [65], and accelerated HIV disease progression
[65,67]. Thus, VDD may exacerbate existing immune dysregulation in HIV infection to fur-
ther increase TB risk, or low vitamin D levels may reflect severity of HIV-related immunosup-
pression. We also note that vitamin D status fluctuates with season, with declines in serum 25–
(OH)D in the winter when UVB exposure is lower [68,69], and in vitro evidence suggests
there is winter-associated increase in HIV replication [68]. Vitamin D also restricts mycobac-
terial growth in the presence of HIV infection [70]. A clinical trial is currently underway to
evaluate the efficacy of vitamin D supplementation in preventing incident TB among adults
with HIV in Tanzania [71]; the results may help clarify role of vitamin D in HIV-associated TB
disease. We also plan to measure inflammatory markers in the Peru cohort to explore associa-
tion between VDD and immune dysregulation.
We considered possible explanations for why we did not detect a significant association
between VDD and TB risk in the Peru cohort, despite its relatively large size. First, since TB
incidence is highest in summer [60,61] and HHCs were recruited when the index case was
diagnosed, they are more likely to have been recruited and assessed when their vitamin D lev-
els were highest. If levels later fell and this fall precipitated TB progression, this would not have
been detected. Secondly, VDR variants are heterogeneously distributed in different popula-
tions and may modify the effect of vitamin D on TB risk. We did not measure VDR variants in
Peru and are therefore unable to assess the prevalence of different VDR genotypes in this
cohort. The Peru study is also limited by the relatively short (1-year) period of follow-up and
the fact that it was only powered to detect a 3-fold or greater difference in TB incidence among
people with VDD.
Our IPD meta-analysis also has some important limitations. Firstly, many possible con-
founding covariates were not measured across all studies. Therefore, we were unable to
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account for other important confounders such as baseline infection status, other micronutrient
levels, and comorbidities, including DM, that might be associated with both VDD and TB risk.
Secondly, although we only examined prospective studies of incident TB disease, the included
studies were all observational, and we cannot exclude the possibility that participants had
early, undiagnosed TB at baseline that lowered vitamin D levels. Although we addressed this
by conducting a sensitivity analysis excluding incident TB cases diagnosed less than 60 days
after enrollment, the smaller number of incident cases diagnosed after 60 days reduced the
power to detect a statistically significant association. Thirdly, we also cannot exclude the possi-
bility of publication bias if studies with nonsignificant findings on the link between vitamin D
and incident TB have remained unpublished. We did not construct a funnel plot to assess pub-
lication bias, because we analyzed seven studies, and guidelines suggest tests for funnel plot
asymmetry are not sufficiently powered to distinguish real asymmetry from chance with fewer
than 10 studies [72]. These studies further used different methods to categorize vitamin D lev-
els and therefore provided effect estimates that are not directly comparable on a funnel plot.
During our systematic review, we attempted to address this by considering data reported from
meeting abstracts, and none met our inclusion criteria. Of note, in the publication identified
after the initial meta-analysis target dates, although Maceda and colleagues found no associa-
tion between serum 25–(OH)D < 75 nmol/L and increased TB risk, our effect estimate for
VDD in the IPD (OR 1.48) falls within the confidence intervals of this small cohort study [39].
We also note that the different 25–(OH)D assays employed in the meta-analysis studies vary in
their sensitivity and precision. However, it is unlikely such variability introduced a bias in one direc-
tion, since within any given study, 25–(OH)D levels were analyzed using the same assay in individu-
als that progressed to TB and nonprogressors. The effect of any imprecision would be more likely
to increase the noise:signal ratio, which would bias results of the analysis toward the null.
Despite the aforementioned limitations, we present findings from one of the largest cohorts
to date evaluating the role of vitamin D on incident TB disease with comprehensive adjust-
ment for possible confounders. The concurrent IPD meta-analysis further increased the sam-
ple size, providing the statistical power to detect more modest associations and enabling the
evaluation of this relationship across different locations and by HIV status.
In conclusion, in our meta-analysis of prospective studies, we found low serum 25–(OH)D
levels were associated with increased risk of future progression to TB disease in a dose-depen-
dent manner. Randomized control trials are needed to determine whether vitamin D supple-
mentation among individuals at high risk can mitigate the risk of developing TB disease.
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